Rett Syndrome is a rare genetic neurological disorder caused primarily by mutations in the MECP2 gene on the X chromosome. It almost exclusively affects girls and is characterised by apparently normal early development followed by a period of regression - loss of purposeful hand use, emergence of stereotyped hand movements, slowed brain growth, gait abnormalities, and severe impairments in language and communication. Parents navigating Rett Syndrome often face challenges around seizure management, sleep disruption, scoliosis, breathing irregularities, and intensive therapy needs. SpecialCircle Research translates the latest peer-reviewed studies, clinical trials from ClinicalTrials.gov, and NIH updates into plain language so every parent can understand what science currently knows - and what is still being discovered.
Approved treatment
This study looked at how people with Rett syndrome in the United States used trofinetide, an FDA-approved treatment, over time.
Source: Journal of medical economics
Approved treatment
A study found that only about one-quarter of eligible individuals with Rett Syndrome received the newly approved medication, Trofinetide, shortly after its approval in the United States.
Source: Journal of health economics and outcomes research
Clinical trial update
Researchers have finished giving the study treatment to all 25 children in a major trial for a new gene therapy called NGN-401.
Source: ClinicalTrials.gov
Review article
A recent review explains how sleep disturbances are common in Rett Syndrome and how they relate to a child's mood and behavior during the day.
Source: PubMed
Gene therapy
A recent review for doctors highlights how new gene-based therapies are changing the way Rett Syndrome is managed.
Source: PubMed (NIH)
Review article
A 2024 expert review offers practical guidance for doctors and families on managing common digestive issues in Rett syndrome, including side effects from the newly approved medication trofinetide.
Source: Expert Review of Gastroenterology & Hepatology
Small human study
A 2023 peer-reviewed study used data from the US Rett Syndrome Natural History Study to identify the top concerns reported by caregivers of people with Rett syndrome and related disorders.
Source: Journal of Neurodevelopmental Disorders
Clinical trial update
In March 2023, the FDA approved Daybue (trofinetide) as the first-ever treatment for Rett syndrome in adults and children 2 years and older. A clinical trial showed statistically significant improvement compared to placebo.
Source: U.S. Food and Drug Administration (FDA)
Clinical trial update
A Phase 1/2/3 clinical trial is testing a one-time gene therapy called TSHA-102, delivered by spinal injection, in females ages 6 to under 22 with classic Rett syndrome.
Source: ClinicalTrials.gov — Taysha Gene Therapies, Inc.
Guideline update
A large group of medical experts created the first consensus-based care guidelines for Rett syndrome, covering the full lifespan from childhood through adulthood.
Source: BMJ Paediatrics Open
Review article
A 2019 review study found that children with Rett syndrome may show subtle signs of the condition before the well-known regression at age 2, suggesting there may be an earlier window for diagnosis and support.
Source: Neuroscience and Biobehavioral Reviews
Clinical trial update
This completed study investigated how factors like family functioning, coping methods, and perceived illness burden impact caregivers of individuals with Rett Syndrome.
Source: National Human Genome Research Institute (NHGRI)
Rett Syndrome is a rare genetic neurological disorder caused primarily by mutations in the MECP2 gene on the X chromosome. It almost exclusively affects girls and is characterised by apparently normal early development followed by a period of regression - loss of purposeful hand use, emergence of stereotyped hand movements, slowed brain growth, gait abnormalities, and severe impairments in language and communication. Parents navigating Rett Syndrome often face challenges around seizure management, sleep disruption, scoliosis, breathing irregularities, and intensive therapy needs. SpecialCircle Research translates the latest peer-reviewed studies, clinical trials from ClinicalTrials.gov, and NIH updates into plain language so every parent can understand what science currently knows - and what is still being discovered. SpecialCircle Research summarises studies from PubMed, NIH, FDA, and ClinicalTrials.gov in plain language for parents. This is not medical advice.
Talk to parents who truly understand
SpecialCircle is a free, private community. Ask questions, share what works, and never feel alone.
We use cookies to operate this site and improve your experience. See our Cookie Policy.